A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea
ClinicalTrials.gov · NCT07018544 · Registry updated: 2025-06-12
- Condition / research focus
- Obesity and Overweight
- Sponsor
- Novo Nordisk A/S
- Countries with listed sites
- South Korea
- Registry dates and results
- Start: 2024-11-19. Completion: 2027-02-28 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- semaglutide (other) — also listed as: Wegovy
Where the study takes place — 8 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Goyang-si, Gyeonggi-do, South Korea